Myeloid Acyl-CoA:Cholesterol Acyltransferase 1 Deficiency Reduces Lesion Macrophage Content and Suppresses

Li-Hao Huang1, Elaina M Melton1, Haibo Li1

  • 1From the Department of Biochemistry, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire 03755 and.

Insights

Targeting Acyl-CoA:cholesterol acyltransferase 1 (Acat1) in myeloid cells reduces atherosclerosis progression. This myeloid-specific approach avoids the severe side effects seen with global Acat1 knockout, offering a promising therapeutic strategy.

Area of Science:

  • Biomedical Science
  • Cardiovascular Research
  • Immunology

Background:

  • Acyl-CoA:cholesterol acyltransferase 1 (Acat1) plays a role in cholesterol metabolism and is a potential drug target for atherosclerosis.
  • Global Acat1 knockout in mice did not prevent atherosclerosis and caused detrimental side effects, including increased apoptosis and reduced lifespan.
  • The specific role of Acat1 in myeloid cells, particularly monocytes and macrophages, within atherosclerosis remained unclear.

Purpose of the Study:

  • To investigate the specific role of Acat1 in myeloid cells during atherosclerosis development.
  • To evaluate the efficacy and safety of targeting Acat1 in a myeloid-specific manner for atherosclerosis treatment.
  • To elucidate the mechanisms by which Acat1 influences leukocyte behavior and lesion progression in atherosclerosis.

Main Methods:

  • Generation of a myeloid-specific Acat1 knockout (Acat1(-M/-M)) mouse model.
  • Utilized the Apoe knockout (Apoe(-/-)) mouse model for atherosclerosis.
  • Analyzed atherosclerotic lesions, leukocyte migration in vivo, and performed studies on isolated monocytes and macrophages.

Main Results:

  • Myeloid-specific Acat1 knockout (Acat1(-M/-M)) in Apoe(-/-) mice significantly decreased plaque area and lesion size.
  • Acat1(-M/-M) reduced macrophage infiltration and cholesterol/cholesteryl ester load in lesions without increasing apoptosis.
  • Inhibition of Acat1 reduced integrin β1 (CD29) expression on monocytes/macrophages, impairing their interaction with the endothelium.

Conclusions:

  • Targeting Acat1 within myeloid cells effectively suppresses atherosclerosis progression.
  • Myeloid-specific Acat1 inhibition avoids the adverse systemic effects associated with global Acat1 knockout.
  • Reduced leukocyte-endothelial interaction, due to decreased integrin β1 expression, is a key mechanism by which Acat1 deficiency impacts atherosclerosis.

Related Concept Videos

Inflammation01:38

Inflammation

Overview
64.1K
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
1.9K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
948
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
578
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
1.9K
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
737